GNPX - Genprex, Inc.
| Previous Close | 1.6800 |
| Open | 1.6879 |
| Bid | 1.5800 x 1000 |
| Ask | 1.7000 x 900 |
| Day's Range | 1.6500 - 1.6500 |
| 52 Week Range | 0.9500 - 12.2400 |
| Volume | 30 |
| Avg. Volume | 49,677 |
| Market Cap | 25.627M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9430 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.25 |
- Business Wire•2 days ago
Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019. Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. Genprex will be among the 30+ presentations by listed and private biotechnology companies at the event.
- GlobeNewswire•14 days ago
Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Promising New Gene Therapies
Gene therapies, the promising treatments pursued by companies such as Genprex Inc. (GNPX), are based on turning [the] problem [of cell mutation] on its head. Once in place, successful gene therapies replace damaged or missing code and help the body cure itself. Creating these treatments is challenging work, and the companies that excel are innovators with the ability to try new approaches.
- GlobeNewswire•15 days ago
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Gene Therapies for Cancer Treatment
NEW YORK, May 08, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.
- Business Wire•15 days ago
Genprex Retains Addison Whitney for Drug Nomenclature Branding
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of leading pharmaceutical branding agency, Addison Whitney. Addison Whitney, a Syneos Health company, will draw from its 28-year history to oversee the proprietary and non-proprietary drug naming process for Genprex’s lead drug candidate, currently known as Oncoprex™ immunogene therapy, for non-small cell lung cancer. Oncoprex immunogene therapy has shown promise in targeting and treating non-small cell lung cancer (NCSLC) through its proprietary technology platform, which transports cancer-fighting genes to cancerous cells by encapsulating the genes into nanoscale hollow spheres, called nanovesicles, which are then administered intravenously.
- Newsfile•last month
Genprex Featured in NetworkNewsAudio Broadcast on Potential Gene Therapy Treatment for Cancer
New York, New York--(Newsfile Corp. - April 12, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio broadcast titled, "Potential Blockbuster Gene Therapy Programs to Watch in 2019."To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/j1WMsTo read the full editorial, visit: http://nnw.fm/YC9iqGenprex already has over 30 issued patents for its platform technologies. The company's promising pipeline currently includes a phase I/II clinical trial underway to evaluate intravenous Oncoprex immunogene therapy in ...
- GlobeNewswire•last month
Genprex (GNPX) Featured in NetworkNewsAudio Broadcast Discussing Gene Therapy Programs on the Cusp of Curing the Incurable
The company’s promising pipeline currently includes a phase I/II clinical trial underway to evaluate intravenous Oncoprex immunogene therapy in combination with another cancer drug, Tarceva, and pre-clinical research of the combination of Oncoprex immunogene therapy with immunotherapies. Gene therapy programs may be on the cusp of curing the incurable, and the companies that deliver these medical miracles are in an ideal position to reap a bonanza of recognition and rewards. Given the promise of Genprex’s pipeline of cancer killers with global blockbuster potential, the company certainly appears to be one to watch.
- Newsfile•last month
Genprex (GNPX) Featured in NetworkNewsWire Publication about Revolutionary Gene Therapies
New York, New York--(Newsfile Corp. - April 11, 2019) - Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled "Potential Blockbuster Gene Therapy Programs to Watch in 2019," visit: http://nnw.fm/YC9iqPerhaps no other disease strikes as much dread and fear as cancer. Many successful treatments are available today that didn't exist just ...
- GlobeNewswire•last month
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Cancer and Gene Therapy Treatment
NEW YORK, April 11, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.
- Business Wire•last month
Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting
TUSC2 Immunogene Therapy Overcomes Resistance to Checkpoint Blockade
- Business Wire•2 months ago
Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission. “Over the past year, we made great progress in advancing the development of our gene therapy platform, including Oncoprex™ immunogene therapy for non-small cell lung cancer,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “I’m pleased with our progress and am excited to continue development of our gene therapies for cancer into 2019 and beyond.
- Newsfile•2 months ago
Genprex Featured in NetworkNewsAudio Publication on Unprecedented Targeting in Cancer Treatment
New York, New York--(Newsfile Corp. - March 29, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio publication titled, "Advanced Medical Technologies Provides Unprecedented Targeting in Cancer Therapy."To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/XRt4dTo read the full editorial, visit: http://nnw.fm/tB7LiA multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (NASDAQ: ...
- GlobeNewswire•2 months ago
Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Advanced Medical Cancer Therapy
A multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (GNPX) (GNPX Profile) is working to bring its potentially life-changing immunogene therapy, Oncoprex, to market. Genprex already has 30 issued patents for its platform technologies and gene therapies.
- GlobeNewswire•2 months ago
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Innovative Cancer Treatments
NEW YORK, March 28, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.
- Newsfile•2 months ago
Genprex Featured in NetworkNewsWire Publication on Innovations in Cancer Therapy
New York, New York--(Newsfile Corp. - March 28, 2019) - Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled "Advanced Medical Technologies Provides Unprecedented Targeting in Cancer Therapy," visit: http://nnw.fm/l3DkVGenprex is on the cusp of potentially delivering life-changing therapeutics for cancer patients by utilizing the company's novel proprietary technology platform. ...
- GlobeNewswire•2 months ago
Genprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsWire
NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with Genprex Inc., a clinical stage gene therapy company developing a new approach to treating cancer. NNW’s Stuart Smith introduces Genprex CEO and Chairman Rodney Varner, JD, for a compelling discussion on the company’s initial product candidate, Oncoprex(TM), an immunogene therapy for non-small cell lung cancer (NSCLC). The American Cancer Society reports that NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancer.
- Newsfile•2 months ago
NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.'s Transformative Work in Gene Therapy
New York, New York--(Newsfile Corp. - March 15, 2019) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Making Profits, Saving Lives with Gene Therapy," featuring Genprex Inc. (NASD: GNPX).To hear the NetworkNewsAudio version, visit: http://nnw.fm/bw1cXTo read the full editorial, visit: http://nnw.fm/Y0ZqHThis evidence of the faith of the markets has helped boost stock values for a range of gene therapy companies, with some seeing triple digit growth. But these companies don't need to be the ...
- GlobeNewswire•2 months ago
NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.’s Innovative Approach to Gene Therapy
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Making Profits, Saving Lives with Gene Therapy,” featuring Genprex Inc. (GNPX). Delivery systems for the genes are as important as the genes themselves. Carriers called vectors deliver the genetic material into the cells.
- Business Wire•2 months ago
Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.
- GlobeNewswire•2 months ago
NetworkNewsWire Announces Publication on Gene Therapy’s Promise for Improving Patient Treatments and Market Profitability
NEW YORK, March 14, 2019 -- via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial.
- GuruFocus.com•2 months ago
5 Biotech Stocks to Keep an Eye on in 2019
The biotech sector is an interesting one to follow. Warning! GuruFocus has detected 2 Warning Sign with CELG. There has been quite a bit of chatter recently surrounding the potential acquisition of the company by Bristol-Myers Squibb (BMY).
- Business Wire•3 months ago
Genprex Strengthens Senior Team and Continues to Advance Operations
Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately.
- Business Wire•3 months ago
Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors
Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of John N. Bonfiglio, PhD, to the company’s Board of Directors. In recent years, Dr. Bonfiglio served as President and CEO of Oragenics, Inc. and most recently as President and COO of TapImmune, Inc., where he helped lay the groundwork for a successful merger with Marker Therapeutics, Inc. in October 2018 by up-listing TapImmune to Nasdaq and starting a robust clinical program in breast and ovarian cancers.
- Business Wire•4 months ago
Genprex to Present at NobleConXV in Fort Lauderdale, Florida
Genprex, Inc. (GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that its President and Chief Operating Officer, Julien Pham, MD, MPH, will deliver a presentation about the company’s unique, leading-edge gene therapies and will also participate in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Florida.
- Business Wire•5 months ago
Genprex to Present at Biotech Showcase™ 2019 in San Francisco
Genprex, Inc. (GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare finance at the Hilton San Francisco Union Square. Genprex is pioneering a new approach to treating cancer–based upon a novel proprietary technology platform–that includes the company’s initial product candidate, Oncoprex™ immunogene therapy.
- Simply Wall St.•5 months ago
Are Insiders Buying Genprex, Inc. (NASDAQ:GNPX) Stock?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
